

From: Bayer US Medical Affairs (no-reply@mail.bayer.com)
To: HCP Email Address
Subject: Update From Bayer Women's Healthcare Medical Affairs
Super Subject: Learn About Publications, On-Demand CEs, and More

[Learn About Publications, On-Demand CE Programs, and More](#)

[View Online](#)

Women's Healthcare

Medical Affairs Updates
December 2025



Welcome to the Bayer Medical Affairs Women's Healthcare December 2025 newsletter. Below you will find information on recent publications and accredited continuing education programs related to Bayer's Women's Healthcare portfolio.

Recent Publications



Elinzanetant received approval from the US Food and Drug Administration (FDA) in October 2025. The pivotal phase 3 clinical trials OASIS 1 and OASIS 2 provided efficacy and safety data for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause, published in *JAMA* ([Pinkerton JV, et al., 2024](#)). Additionally, the long-term safety of elinzanetant was evaluated in OASIS 3, with findings published in *JAMA* ([Panay N, et al., 2025](#)).

Panay N, et al.	Elinzanetant for the treatment of vasomotor symptoms associated with menopause: Phase 3 randomized clinical trial	<i>JAMA Intern Med</i> (Sep 2025)
Saadedine M, et al.	Treatment patterns in women with breast cancer and endocrine therapy-related menopausal symptoms: a cohort study from the United States, United Kingdom, and Germany	<i>Menopause</i> (Sep 2025)
Soares C, et al.	Impact of sleep disturbances on health-related quality of life in postmenopausal women: a systematic review	<i>Menopause</i> (Sep 2025)
Young Moss S, et al.	Advances in pharmacotherapy for menopausal vasomotor symptoms	<i>Drugs</i> (Sep 2025)
Charafi L, et al.	Characterization and treatment patterns of peri/menopausal and postmenopausal women with and without vasomotor symptoms in a retrospective database study	<i>Womens Health Rep (New Rochelle)</i> (Aug 2025)
Saadedine M, et al.	Treatments in women experiencing natural menopause: A cohort study from the USA, the UK and Germany	<i>Climacteric</i> (Jul 2025)
Haberland C, et al.	Qualitative exploration of women's experiences of vasomotor symptoms to support the content validity of patient-reported outcomes	<i>J Patient Rep Outcomes</i> (Jul 2025)
Cardoso F, et al.	Elinzanetant for vasomotor symptoms from endocrine therapy for breast cancer	<i>NEJM</i> (Jun 2025)

For additional publications, please visit medicalaffairs.bayer.com

Accredited Continuing Education



This information is being offered for your educational purposes only. Bayer is not responsible for, nor has any control over, the content presented by any independent website or entity.

A Snapshot Into Women's Health: Managing Intrauterine Contraception, Placement Pain, and Anxiety for Optimal Patient Outcomes

Upon completion of this activity, participants should be able to:

- Assess the range of pain and anxiety experienced by patients undergoing IUD procedures and apply a structured algorithm to evaluate individual risk factors and select appropriate pain management strategies
- Design and implement a multimodal approach to pain management for IUD placement that integrates best practices, including pharmacological and non-pharmacological interventions, to optimize patient comfort and experience

0.5-hour presentation webcast. Available until July 30, 2026.

[CLICK TO ACCESS](#)

Targeting the Root Cause: New & Emerging Therapies for Menopausal VMS

Upon completion of this activity, participants should be able to:

- Discuss the clinical trial data for new and emerging non-hormonal therapies

0.25-hour podcast. Available until August 8, 2026.

[CLICK TO ACCESS](#)

Consider Personalizing Care: Identifying the Right Patients for New Menopause Treatments

Upon completion of this activity, participants should be able to:

- Integrate routine and individualized screening methods to identify patients with menopausal VMS, with attention to healthcare disparities
- Integrate new and emerging agents into the treatment of women with menopausal VMS, based on patient characteristics and preference

0.25-hour podcast. Available until August 8, 2026.

[CLICK TO ACCESS](#)

Let's Replace Silence With Science: Patient and Provider Perspectives on Addressing the Substantial Impact of Menopausal Symptoms

Upon completion of this activity, participants should be able to:

- Describe the impact of menopausal symptoms and their undertreatment across physical, psychosocial, and socioeconomic domains of women's personal and professional lives
- Identify key strengths and limitations of recommended hormonal and non-hormonal treatments for vasomotor symptoms associated with menopause
- Explain the role of KNDy neurons in the hypothalamus in hormonal regulation and the pathophysiology of vasomotor symptoms, sleep disorders, and mood disturbances associated with menopause

0.5-hour on-demand video. Available until July 30, 2027.

[CLICK TO ACCESS](#)

Other Research and Educational Resources

Bayer's US Medical Affairs website is an educational resource for US healthcare providers to access scientific and clinical information.

Available at medicalaffairs.bayer.com.

If you have any questions, visit <https://askmed.bayer.com>.



© 2025 Bayer. Bayer and the Bayer Cross are registered trademarks of Bayer. All rights reserved.

Bayer Corporation, 100 Bayer Boulevard, Whippany, NJ 07981
November 2025. MA-PFM-WHC-US-0099-1

Please note that this email address is not monitored for replies.

If you would like to contact us, visit our [Contact us](#) section online.

[Terms of Use](#) | [Privacy Policy](#) | [Unsubscribe](#)

This message is brought to you by Bayer US Medical Affairs.